Zentiva to Acquire Alvogen’s Generics and OTC Business in Central and Eastern Europe

 Zentiva to Acquire Alvogen’s Generics and OTC Business in Central and Eastern Europe

Zentiva to Acquire Alvogen’s Generics and OTC Businesses in Central and Eastern Europe

Shots:

  • Zentiva acquires Alvogen’s CEE market consisting of 200+ generics and OTC therapies across multiple therapeutics areas which include brands like Lactacyd, Persen, EuBiotic. The transaction is expected to be closed in Q1’20
  • The focus of the acquisition is to combine two leading branded generics and OTC business in the CEE region and will strengthen Zentiva’s geographical footprint and complements generics and OTC portfolio
  • Alvogen’s divestiture of its European business will allow its focus on development, growth and expansion in other therapeutic areas as it is currently focusing on biosimilars through its sister company, Alvotech

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Idnes

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post